FBN1 and metabolic dysfunction-associated steatohepatitis: These findings suggest that AAV‐shAsprosin can compensate for the limitations of fenofibrate in the treatment of MASH, and that inhibition of hepatic asprosin may be an effective option for the treatment of MASLD/MASH.